Conflicts of interest The authors have stated explicitly that there are no conflicts of interest in connection with this article.
SHORT RESEARCH REPORT
On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome – an epi-analysis
Article first published online: 1 NOV 2012
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology
Acta Obstetricia et Gynecologica Scandinavica
Volume 91, Issue 12, pages 1460–1464, December 2012
How to Cite
VANKY, E., DE ZEGHER, F., DÍAZ, M., IBÁÑEZ, L. and CARLSEN, S. M. (2012), On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome – an epi-analysis. Acta Obstetricia et Gynecologica Scandinavica, 91: 1460–1464. doi: 10.1111/aogs.12015
Please cite this article as: Vanky E, De Zegher F, Díaz M, Ibáñez L, Carlsen SM. On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome – an epi-analysis. Acta Obstet Gynecol Scand. 2012; 91:DOI: 10.1111/aogs.12015.
- Issue published online: 5 DEC 2012
- Article first published online: 1 NOV 2012
- Accepted manuscript online: 24 SEP 2012 10:25PM EST
- Received: 29 February 2012 Accepted: 13 September 2012
- polycystic ovary syndrome;
- preterm delivery;
- gestational diabetes;
Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS). We performed an epi-analysis of two randomized controlled trials. The participants were 313 women aged 18–42 years with PCOS who had singleton pregnancies. They were randomized to metformin or placebo treatment from first trimester until delivery. We analysed the prevalence of late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes according to both the intention-to-treat principle and per protocol analysis. The metformin-treated patients had less late miscarriage/preterm delivery; five (3%) vs. 18 (11%) in the placebo group (p < 0.01). There was no difference in the prevalence of gestational diabetes and pre-eclampsia between the metformin and the placebo group. In this epi-analysis, metformin treatment during pregnancy seems to reduce early delivery in women with PCOS. We believe that further randomized studies should be performed before firm conclusions can be drawn.